Hepatitis/MASH

An increasing number of patients with decompensated cirrhosis are receiving direct-acting antiviral treatment and attaining sustained virologic response of hepatitis C, however, their long-term outcomes are unclear.

Study finds chronic hepatitis C virus infection should not delay the initiation of an urgent cancer therapy.

Achievable steps could be taken to reach the World Health Organization goal of eliminating hepatitis B and C virus infections as public health threats by 2030.

A novel vaccine to prevent hepatitis C infection has been tested in Baltimore and at two other sites in the United States.

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

The study was the first to compare patients with hepatitis C treated with direct-acting antiviral drugs and those untreated for long-term risks.

Because pregnancy is one of the few times individuals are in contact with the health system and covered by health insurance, there is a cost-effective opportunity to screen for hepatitis C virus.

Study finds that glecaprevir/pibrentasvir pan-genotypic efficacy for hepatitis C virus is achieved regardless of whether patients are concurrently receiving gastric acid-reducing drugs.

New research supports the use of direct-acting antiviral therapy for all individuals with chronic hepatitis C infection.

Longitudinal study of direct-acting antivirals for hepatitis C virus infection finds that treatment provides clinical benefit beyond virologic response, reducing risk for both all-cause mortality and for liver cancer.

A novel method of inactivating hepatitis C virus in donor lungs could increase transplantations for patients with end stage lung disease.

Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report

Analysis finds universal screening for hepatitis C virus infection would be cost effective and provide greater benefit than the currently recommended birth cohort screening.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The 2010 remanufacturing of Purdue Pharma's OxyContin (oxycodone) into an "abuse-deterrent formulation" has been identified as a key contributing factor in opioid abusers switching to heroin injections and the corresponding surge in hepatitis C virus (HCV) infections, according to a new Rand Corporation study.

Injection drug use has been identified as a predominant risk factor for hepatitis C infection and the opioid epidemic has been suggested as a driver of a recent rise in infections.

HIV-positive patients with hepatocellular carcinoma had an adjusted 24% increased hazard of death compared to their HIV-negative peers.

The global hepatitis C virus epidemic faces several barriers and meeting WHO target goals will be difficult unless a vast strategy is implemented.

Scaling up prevention, treatment, and screening interventions can make substantial strides toward global hepatitis C elimination.

Post-cure care for hepatitis C can reduce the risk of liver disease progression in those with advanced fibrosis and ongoing risk factors for liver injury.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

Top news of the day across the health care landscape

Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.